These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33052555)

  • 21. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
    Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
    Barnes JI; Lin JK; Gupta D; Owens DK; Goldhaber-Fiebert JD; Kunz PL
    J Natl Compr Canc Netw; 2020 Sep; 18(9):1200-1209. PubMed ID: 32886901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
    Ryan P; Phan AT; Adelman DT; Iwasaki M
    Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
    Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
    Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study.
    Ito T; Fujimori N; Honma Y; Kudo A; Hijioka S; Katsushima S; Kimura Y; Fukutomi A; Hisamatsu S; Nakajima A; Shimatsu A
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e153-e161. PubMed ID: 32757459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
    Lepage C; Dahan L; Bouarioua N; Toumpanakis C; Legoux JL; Le Malicot K; Guimbaud R; Smith D; Tougeron D; Lievre A; Cadiot G; Di Fiore F; Bouhier-Leporrier K; Hentic O; Faroux R; Pavel M; Borbath I; Valle JW; Rinke A; Scoazec JY; Ducreux M; Walter T
    Dig Liver Dis; 2017 May; 49(5):568-571. PubMed ID: 28292641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.
    Sood A; Munir M; Syed O; Mehta V; Kaur R; Kumar A; Sridhar A; Sood A; Gupta R
    Expert Opin Drug Saf; 2024 Aug; 23(8):949-957. PubMed ID: 38847075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
    Ferolla P; Berruti A; Spada F; Brizzi MP; Ibrahim T; Marconcini R; Giuffrida D; Amoroso V; La Salvia A; Vaccaro V; Faggiano A; Colao A; Volante M; Ghizzoni S; Mazzanti P; Houchard A; Fazio N
    Neuroendocrinology; 2023; 113(3):332-342. PubMed ID: 36044870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
    Prasad V; Srirajaskanthan R; Toumpanakis C; Grana CM; Baldari S; Shah T; Lamarca A; Courbon F; Scheidhauer K; Baudin E; Truong Thanh XM; Houchard A; Dromain C; Bodei L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2358-2371. PubMed ID: 32062681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies.
    Adelman DT; Van Genechten D; Megret CM; Truong Thanh XT; Hand P; Martin WA
    Adv Ther; 2019 Dec; 36(12):3409-3423. PubMed ID: 31612358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
    Bajetta E; Procopio G; Catena L; Martinetti A; De Dosso S; Ricci S; Lecchi AS; Boscani PF; Iacobelli S; Carteni G; De Braud F; Loli P; Tartaglia A; Bajetta R; Ferrari L
    Cancer; 2006 Nov; 107(10):2474-81. PubMed ID: 17054107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.
    Grenader T; Pavel ME; Ruszniewski PB; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Truong Thanh XM; Caplin ME;
    Anticancer Drugs; 2020 Mar; 31(3):216-222. PubMed ID: 31977567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.
    Buil-Bruna N; Garrido MJ; Dehez M; Manon A; Nguyen TX; Gomez-Panzani EL; Trocóniz IF
    Clin Pharmacokinet; 2016 Apr; 55(4):461-73. PubMed ID: 26416534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety of lanreotide for neuroendocrine tumor.
    Godara A; Siddiqui NS; Byrne MM; Saif MW
    Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
    Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
    BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.
    Mirakhur B; Pavel ME; Pommier RF; Fisher GA; Phan AT; Massien C; Liyanage N; Lowenthal SP; Vinik AI
    Endocr Pract; 2018 Aug; ():. PubMed ID: 30084687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.
    Chen JS; Bai LY; Cheng HH; Chan SL; Zou JY; Shi X; Houchard A; Truong-Thanh XM; Chen MH
    Oncol Ther; 2024 Aug; ():. PubMed ID: 39215958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
    Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT
    J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.